For Canadian Residents Only |
Image: Sanofi Pasteur Logo
For Canadian Residents Only   | Version Française
FLUZONE® Quadrivalent Vaccine | FLUZONE® High-Dose Vaccine |     
Flu Facts
Find FLUZONE® HD
E-mail button Print button

Thank you for your interest in FLUZONE® High-Dose.
Please come back in September to check the new list of clinics for the 2017-2018 flu season


FLUZONE® High-Dose Vaccine
Image: If you remember when rock was young, then we have a flu vaccine specially formulated for you.
Image: If you remember when rock was young, then we have a flu vaccine specially formulated for you. Image: Specially formulated for people 65+

A flu vaccine specially formulated for people 65 years and older1.

As you get older, your immune system weakens. Therefore, you don't have as high an antibody response after receiving the traditional flu vaccine to help your body fight off the flu2. FLUZONE® High-Dose vaccine is made for people 65+ to help promote a stronger protection against flu than a regular flu vaccine3.

Seniors represent 16% of Canada’s population4. Yet, in 2014-2015, adults 65+ accounted for 70% of influenza-related hospitalizations and 91% of influenza-related deaths5.

Demonstrated to protect against the flu better than our regular flu shot in adults 65 years of age and older3, 6.

In adults 65 years of age and older, FLUZONE® High-Dose vaccine has been demonstrated to be significantly more effective than a standard dose vaccine in preventing confirmed influenza illness — 24.2% more effective*1,6. It has 4 times the antigen of a regular flu shot for a stronger protection against flu8.

Image: 24 % more effective than standard dose influenza vaccine
* In a clinical study, FLUZONE® High-Dose vaccine was 24.2% more effective than FLUZONE® vaccine in preventing laboratory-confirmed influenza.1, 6

Flu complications can be especially devastating when you're 65 or older8.

In the 2014-2015 flu season, up to 91% of flu-related deaths and 70% of flu-related hospitalizations in Canada occurred in people 65 or older5. That's why it's important to take extra precautions to help protect yourself.

So what can you do? Get vaccinated8. It's the best way to help protect yourself from influenza9. It's also helpful to take preventive measures such as7:

  • Encouraging others to cover coughs and sneezes

  • Washing hands

  • Staying away from people who are sick

Image: According to Canada's National Advisory Committee on Immunization(NACI)

Get FLUZONE® High-Dose vaccine

Thank you for your interest in FLUZONE® High-Dose.
Please come back in September to check the new list of clinics for the 2017-2018 flu season.

Get FLUZONE® High-Dose vaccine

  • Thank you for your interest in FLUZONE® High-Dose.
    Please come back in September to check the new list of clinics for the 2017-2018 flu season.


Have questions? Get answers.

How can I learn more about influenza?

Indication and Safety Information:

FLUZONE® High-Dose is a vaccine used to prevent influenza in adults 65 years of age and older. Influenza (or flu) is an infection caused by the influenza virus. Annual vaccination using the current vaccine is recommended for prevention against influenza as immunity declines in the year following vaccination. Persons with a history of severe allergic reaction to eggs or egg products or any component of FLUZONE® High-Dose should not receive the vaccine. FLUZONE® High-Dose will only protect against the strains of influenza virus contained in the vaccine or those that are closely related. FLUZONE® High-Dose will not protect against any other strains of influenza virus. FLUZONE® High-Dose is not indicated for the prevention of hospitalization or death after the onset of disease. As with all vaccines, FLUZONE® High-Dose does not protect 100% of people immunized. The most common side effects are pain at the injection site, muscle ache. Talk to your doctor, nurse or pharmacist to see if this vaccine is right for you or your child. For more information, visit www.sanofipasteur.ca.

References

  1. FLUZONE® High-Dose Product Monograph. Sanofi Pasteur Limited. May, 2016.
  2. Reber AJ, Chirkova T, Kim JH, et al. Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. Aging Dis 2012 Feb;3(1):68-90.
  3. National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2016-2017. May 2016. http://www.phac-aspc.gc.ca/naci-ccni/flu-2016-grippe-eng.php. Accessed on May 10, 2016.
  4. Statistics Canada. 2015 Population estimate for Canada. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo31a-eng.htm. Accessed on February 10, 2016.
  5. Public Health Agency of Canada (PHAC). FluWatch. May 3 to May 9, 2015.
  6. DiazGranados, C., Dunning, A., Kimmel, M. et al. Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults. N Engl J Med 2014;371:635-45.
  7. World Health Organization (WHO) Writing Group. Nonpharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006;12(1):88–94
  8. National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2015-2016. July 2015. http://www.phac-aspc.gc.ca/naci-ccni/flu-2015-grippe-eng.php. Accessed on February 10, 2016.
  9. Public Health Agency of Canada. Getting the facts - then get your flu shot. http://www.phac-aspc.gc.ca/chn-rcs/flufacts-eng.php. Accessed on February 11, 2016.

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Click here to close this window and return to the site.